This content is for educational purposes only. Not medical advice. Always consult a licensed healthcare professional before using any peptides.

Back to Library
Weight LossModerate RiskFDA-approved (Saxenda/Victoza)

Liraglutide

The Daily GLP-1

Liraglutide is a GLP-1 receptor agonist administered daily, FDA-approved as Saxenda for weight management and Victoza for type 2 diabetes. While slightly less potent than once-weekly semaglutide, it offers a well-established safety profile with decades of clinical data. Its daily dosing allows for more granular dose control and quicker dose adjustments.

If You Take This

  • FDA-approved for weight loss (Saxenda) and diabetes (Victoza)
  • Average 8-10% body weight reduction
  • Decades of clinical safety data
  • Daily dosing allows precise dose control
  • Reduces cardiovascular risk factors
  • Improves glycemic control and insulin sensitivity

Protocol

Dosing
Start at 0.6mg subcutaneous daily for 1 week, increase by 0.6mg weekly until target dose of 3.0mg daily (Saxenda protocol).
Cycle Length
Ongoing — typically 6-12+ months. Slow dose titration over first 5 weeks.
Half-Life
13 hours (daily dosing)
Best Time
Same time each day, any time
Method
Subcutaneous injection (abdomen, thigh, or upper arm)

Stacks Well With

BPC-157 for GI side effect managementMetformin (complementary in diabetic patients)

Avoid With

Other GLP-1 agonists (do not combine with semaglutide)Insulin secretagogues without monitoring

Side Effects

  • Nausea (most common, usually transient)
  • Diarrhea or constipation
  • Headache
  • Injection site reactions
  • Decreased appetite (therapeutic effect)
  • Rare: pancreatitis, gallbladder issues

Where to Buy

Not Currently Available

Liraglutide is not currently available from our partner vendors. This may be due to regulatory status, limited supply, or vendor restrictions. Check back later as we regularly update our vendor listings.

Add to My StackBack to Library

For educational and informational purposes only. Not medical advice. Always consult a healthcare provider before starting any peptide protocol.